Clinical Trials in New York State

Showing 10681-10700 of 14,718 trials

First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis

NCT00875446

The drug being tested in this study is GSK1223249. It is being developed by GlaxoSmithKline to treat symptoms in patients with Amyotrophic Lateral Sclerosis (ALS). The drug works by inhibiting the protein that prevents nerve growth. This will be the first time the drug will be given to man. The trial is expected to involve approximately 76 patients. The study objective is to investigate the tolerability, safety and the way the body handles GSK1223249 after a range of single doses or repeat dose escalation in patients with ALS.

Amyotrophic Lateral Sclerosis

GlaxoSmithKline76 participantsStarted May 2009

Baltimore, Maryland, United States • New York, New York, United States • Syracuse, New York, United States +9 more locations

COMPLETEDPhase 297 miles

Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease

NCT00620451

This study was conducted to assess the safety and efficacy of larazotide acetate versus placebo in inducing remission in subjects with active celiac disease.

Celiac Disease

9 Meters Biopharma, Inc.105 participantsStarted Feb 2008

Orange, California, United States • San Francisco, California, United States • Torrington, Connecticut, United States +30 more locations

First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis

Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate in Subjects With Active Celiac Disease

Find Trials by Condition in New York State

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen

Time to Eugonadal Range, Time to Steady State and Drying Time

Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001

Clinical Trials to Reduce the Risk of Antimicrobial Resistance

Study to Assess the Efficacy of Larazotide Acetate for the Treatment of Celiac Disease

Oral Rivaroxaban in Children With Venous Thrombosis

Inhaled Nitric Oxide Study for Respiratory Failure in Newborns

Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure

Physiologic Definition of Bronchopulmonary Dysplasia

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment

N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Bone Health Observational Study

Delayed Cord Clamping in VLBW Infants

Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD